Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2006017859) ASSAYS AND METHODS USING BIOMARKERS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A method for predicting the sensitivity of a mammalian tissue or cells sample to death receptor antibody, comprising the steps of:
obtaining a" mammalian tissue or cell sample;
examining the tissue or cell sample to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3,
fucosyltransferase 6, sialyl Lewis A and/or X antigen (s), wherein expression of said one or more biomarkers is predictive that said tissue or cell sample is sensitive to apoptosis- inducing activity of one or more death receptor antibodies.

2. The method of claim 1 wherein said expression of one or more biomarkers is examined by detecting mRNA expression of fucosyltransferase 3 or fucosyltransferase 6.

3. The method of claim 1 wherein said expression of one or more biomarkers is examined by immunohistochemistry to detect expression of sialyl Lewis A and/or X antigen (s) .

4. The method of claim 1 further comprising the step of examining expression of DR4 , DR5, DcRl, or DcR2 receptors in said tissue or cell sample .

5. The method of claim 1 wherein tissue or cell sample comprises cancer tissue or cells.

6. The method of claim 5 wherein said cancer cells are colon, colorectal, gastrointestinal, or pancreatic cancer cells or tissue.

7. The method of claim 1 wherein said one or more death receptor
antibodies are DR5 or DR4 antibodies.

8. A method for inducing apoptosis in a mammalian tissue or cell sample, comprising the steps of:
obtaining a mammalian tissue or cell sample;
examining the tissue or cell sample to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3,
fucosyltransferase 6, sialyl Lewis A and/or X antigen (s), and
subsequent to detecting expression of said one or more biomarkers, exposing said tissue or cell sample to an effective amount of death receptor agonist antibody.

9. The method of claim 8 wherein said expression of one or more biomarkers is examined by testing for mRNA expression of fucosyltransferase 3 or fucosyltransferase 6.

10. The method of claim 8 wherein said expression of one or more
biomarkers is examined by immunohistochemistry to detect expression of sialyl Lewis A and/or X antigen (s) .

11. The method of claim 8 further comprising the step of examining expression of DR4, DR5, DcRl or DcR2 receptors in said tissue or cell sample .

12. The method of claim 8 wherein said tissue or cell sample comprises cancer tissue or cells.

13. The method of claim 11 wherein said cancer cells are colon,
colorectal, gastrointestinal, or pancreatic cancer cells or tissue.

14. The method of claim 8 wherein said cells are exposed to an effective amount of DR5 or DR4 agonist antibodies.

15. A method of treating a disorder in a mammal, such as an immune related disorder or cancer, comprising the steps of:
obtaining a tissue or cell sample from said mammal;
examining the tissue or cell sample to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3,
fucosyltransferase 6, sialyl Lewis A and/or X antigen(s), and
subsequent to detecting expression of said one or more biomarkers, administering to said mammal an effective amount of death receptor agonist antibody.

16. The method of claim 15 wherein said expression of one or more biomarkers is examined by detecting mRNA expression of fucosyltransferase 3 or fucosyltransferase 6.

17. The method of claim 15 wherein said expression of one or more biomarkers is examined by immunohistochemistry to detect expression of sialyl Lewis A and/or X antigen (s) .

18. The method of claim 15 further comprising the step of examining expression of DR4, DR5, DcRl or DcR2 receptors in said tissue or cell.

19. The method of claim 15 wherein tissue or cell sample comprises cancer tissue or cells.

20. The method of claim 19 wherein said cancer cells or tissue comprises colon, colorectal, gastrointestinal, or pancreatic cancer cells or tissue.

21. The method of claim 14 wherein an effective amount of DR5 or DR4 agonist antibody is administered to said mammal.

22. The method of claim 15 wherein a chemotherapeutic agent (s) or radiation therapy is also administered to said mammal.

23. The method of claim 15 wherein a cytokine, cytotoxic agent or growth inhibitory agent is also administered to said mammal .

24. The method according to any one of claims 7, 14, or 21 wherein said antibody is DR5 monoclonal antibody.

25. The method according to any one of claims 7, 14, or 21 wherein said antibody is DR4 monoclonal antibody.

26. The method according to any one of claims 7, 14, or 21 wherein said antibody is a human monoclonal antibody which binds DR5.

27. The method according to any one of claims 7, 14, or 21 wherein said antibody is a human monoclonal antibody which binds DR4.

28. The method according to any one of claims 7, 14, or 21 wherein said antibody is a chimeric or humanized monoclonal antibody which binds DR5.

29. The method according to any one of claims 7, 14, or 21 wherein said antibody is a chimeric or humanized monoclonal antibody which binds DR4.

30. The method according to any one of claims 7, 14, or 21 wherein said antibody is a DR5 antibody which binds an amino acid sequence
comprising residues 1-411 of Figure 3A (SEQ ID NO: 5) .

31. The method according to any one of claims 7, 14, or 21 wherein said antibody is a DR4 antibody which binds an amino acid sequence
comprising residues 1-468 of Figure 2 (SEQ ID NO: 3) .

32. A method for predicting the sensitivity of mammalian colon or colorectal cancer cells to DR5 receptor antibody, comprising the steps of: obtaining mammalian colon or colorectal cancer cells,-examining the cancer cells to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3, fucosyltransferase 6, sialyl Lewis A and/or X antigen (s), wherein expression of said one or more biomarkers is predictive that said cancer cells are sensitive to
apoptosis- inducing activity of DR5 receptor antibody.

33. The method of claim 32 wherein said DR5 receptor antibody is a human, chimeric, or humanized antibody.

34. The method of claim 32 wherein said DR5 receptor antibody binds an amino acid sequence comprising residues 1-411 of Figure 3A (SEQ ID NO: 5) . 35. A method for inducing apoptosis in mammalian colon or colorectal cancer cells, comprising the steps of:
obtaining mammalian colon or colorectal cancer cells,-examining the cancer cells to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3, fucosyltransferase 6, sialyl Lewis A and/or X antigen (s), and
subsequent to detecting expression of said one or more biomarkers, exposing said tissue or cell sample to an effective amount of DR5 agonist antibody.

36. The method of claim 35 wherein said DR5 agonist antibody is a human, chimeric, or humanized antibody.

37. The method of claim 35 wherein said DR5 agonist antibody binds an amino acid sequence comprising residues 1-411 of Figure 3A (SEQ ID NO: 5) .

38. A method of treating colon or colorectal cancer in a mammal,
comprising the steps of:
obtaining a colon or colorectal cancer sample from said mammal;
examining the cancer sample to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3, fucosyltransferase 6, sialyl Lewis A and/or X antigen (s), and
subsequent to detecting expression of said one or more biomarkers, administering to said mammal an effective amount of DR5 agonist antibody.

39. The method of claim 38 wherein said DR5 agonist antibody is a human, chimeric, or humanized antibody.

40. The method of claim 38 wherein said DR5 agonist antibody binds an amino acid sequence comprising residues 1-411 of Figure 3A (SEQ ID N0-.5) .